文献速递肝胆胰外科胃肠外科

ALPPS治疗晚期结直肠癌肝转移的生存分析:与姑息性系统治疗的病例匹配比较

Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy.
PubMed 文献 · Surgery · 2016-12-27

本研究基于国际ALPPS注册数据库,筛选出70例按预设标准定义为「其他方式不可切除」的结直肠癌肝转移患者,将其与CAIRO和CAIRO2两项III期试验中接受姑息性系统治疗的患者进行倾向性评分匹配。

核心结论

  • 对于按预设标准定义为其他方式不可切除的晚期结直肠癌肝转移患者,接受ALPPS的早期肿瘤学结局并不优于匹配的姑息性系统治疗患者。
  • 严格的患者选择对于改善ALPPS outcomes至关重要。

研究设计与样本

  • 研究基于国际ALPPS注册数据库,纳入295例结直肠癌肝转移患者,其中70例符合「其他方式不可切除」标准。
  • 不可切除标准定义为满足以下至少2条:≥6个转移灶、≥2个未来残肝转移灶、≥6个受累肝段(排除第1段)。
  • 采用倾向性评分将70例ALPPS患者与CAIRO和CAIRO2两项III期转移性结直肠癌试验中接受姑息性系统治疗的患者进行匹配。

关键数值与推荐

  • 其他方式不可切除的ALPPS患者定义:至少满足≥6个转移灶、≥2个未来残肝转移灶、≥6个受累肝段(排除第1段)中的2条。

临床怎么用

  • 对于晚期结直肠癌肝转移患者,ALPPS不应被视为优于姑息性系统治疗的默认选择,需严格评估适应证。
  • 满足≥2条不可切除标准的患者ALPPS术后无病生存和总生存较差,应充分告知并谨慎选择。
  • 多学科团队应结合转移灶数目、未来残肝转移灶及受累肝段等因素综合决策。

局限性

  • 研究为回顾性注册数据分析,非随机对照试验,存在选择偏倚可能。
  • 与历史临床试验患者进行倾向性评分匹配,无法完全消除混杂因素。
  • 样本量有限(70例不可切除ALPPS患者),统计效能可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows the resection of colorectal liver metastases with curative intent which would otherwise be unresectable and only eligible for palliative systemic therapy. This study aimed to compare outcomes of ALPPS in patients with otherwise unresectable colorectal liver metastases with matched historic controls treated with palliative systemic treatment. METHODS: All patients with colorectal liver metastases from the international ALPPS registry were identified and analyzed. Survival data were compared according to the extent of disease. Otherwise unresectable ALPPS patients were defined by at least 2 of the following criteria: ≥6 metastasis, ≥2 future remnant liver metastasis, ≥6 involved segments excluding segment 1. These patients were matched with patients included in 2, phase 3, metastatic, colorectal cancer trials (CAIRO and CAIRO2) using propensity scoring in order to compare survival. RESULTS: Of 295 patients with colorectal liver metastases in the ALPPS registry, 70 patients had otherwise unresectable disease defined by the proposed criteria. Two-year overall survival was 49% and 72% for patients with ≥2 and <2 criteria, respectively (P = .002). Median disease-free survival was 6 months compared to 12 months (P < .001) in the ≥2 and <2 criteria groups, respectively. Median overall survival was comparable between ALPPS patients with ≥2 criteria and case-matched patients who received palliative treatment (24.0 vs 17.6 months, P = .088). CONCLUSION: Early oncologic outcomes of patients with advanced liver metastases undergoing ALPPS were not superior to results of matched patients receiving systemic treatment with palliative intent. Careful patient selection is essential in order to improve outcomes.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Olthof PB, Huiskens J, Wicherts DA, et al. Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. Surgery. 2016. PMID: 28038862. doi:10.1016/j.surg.2016.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。